In a Feb. 15 hearing by the Select Subcommittee on the Coronavirus Pandemic, U.S. health officials side-stepped a question when asked whether the U.S. Food and Drug Administration (FDA) is actively conducting extended safety surveillance on those who received early COVID-19 vaccines.
Rep. Nicole Malliotakis (R-N.Y.) asked Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, whether the FDA is conducting active surveillance and if there are any specific health markers they’re studying that may signal trends requiring further inquiry.
“Every time we go through and do the safety surveillance, we start back, and it goes back to 2020. In some cases where we’re looking for certain things, we might use a different window, but indeed, we have to look from the beginning of the period of surveillance. I can turn it over to Dr. Jernigan because he can speak for CDC [Centers for Disease Control and Prevention] in that regard,” Dr. Marks said.
Read Full Article Here